/
Methods Results Adi   Pais Methods Results Adi   Pais

Methods Results Adi Pais - PowerPoint Presentation

lily
lily . @lily
Follow
342 views
Uploaded On 2022-06-28

Methods Results Adi Pais - PPT Presentation

Chidambaram Gunanathan Raanan Margalit Inbal Eti Biton Ady Yosepovich David Milstein Hadassa Degani In Vitro and In Vivo Molecular Imaging of the ID: 926601

pta epta contrast tpta epta pta tpta contrast breast targeted mri tumors vivo cell min cancer cells relaxivity analysis

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Methods Results Adi Pais" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Methods

Results

Adi

Pais

, Chidambaram

Gunanathan

,

Raanan

Margalit

,

Inbal

Eti

Biton

,

Ady

Yosepovich

,

David Milstein, Hadassa Degani

In Vitro and In Vivo Molecular Imaging of the Estrogen Receptor using Novel ER-Targeted MRI Contrast Agents

Conclusions

We thank Tamar

Kreizman, Drs Dalia Seger & Edna Furman-Haran, Minjun Li & Prof. Joel Sussman for contributing to the success of this project This work was supported by Israel Science Foundation grant 235/08 and National Institutes of Health Grant CA 42238, and by Ernst and Anni DeutschH. Degani is the incumbent of the Fred and Andrea Fallek Professorial Chair for Breast Cancer Research

Acknowledgement

Introduction

Estrogen

receptor

alpha

(ER) is a member of the nuclear receptor family and serves as a key regulator in the female reproductive organs, including the mammary gland. ER is over expressed in ~70% of breast cancers and is a

prominent prognostic

marker for breast cancer and serves to select patients for hormonal therapy. we describe a novel method for Imaging ER in vivo using targeted ER contrast agents.

EPTA-Gd

PTA-Gd

TPTA-Gd

17β-estradiol

tamoxifen

Anatomical image

ER+

Cell implantation:

mammary fat pad

,

Left:

WT MDA-MB-231 : ER-Right: Tet Inducible ER transfected MDA-MB-231 : ER+

ER induction: 0.2 mg/ml tetracycline in drinking water

Day 14

Days

21-35

Ovariectomy

Day 7

DCE-MRI

Day 0

ER-

ER

Immunostaining

Orthotopic

Human Breast Cancer

in Female SCID

In vivo MRI protocol

9.4T Biospec AVANCE II spectrometer (Bruker)T2W anatomical-RARE SET1W-3DGE, FLASH, TE/TR/flip angle 2.5ms/15ms/40º Acquisition time 0.75-1.5 minSpatial resolution 0.156x0.156x1.2 mm3IV bolus injection:

EPTA-Gd 0.03-0.075 mmol/kgTPTA-Gd 0.075 mmol/kg PTA-Gd 0.15 mmol/kg

post contrast

coronal image

EPTA-

Gd

TPTA-Gd

PTA-Gd

Blood

Kidney

m

2

=0.03 min

-1

m2=0.003, min-1

m2=0.04, min-1

Fast clearance

Fast clearance

Slow clearance

Cb(t)= Dose(a1e-m1t + a2e-m2t )

 Gd-complexBinding Affinity to ERKi (μM)T1 Relaxivity 9.4Tr1 (mM·s)-1EPTA-Gd0. 97± 0.076.8±0.7TPTA-Gd0.13 ± 0.014.7±0.1PTA-Gd-3.0±0.1

Cellular Studies: Hormonal-Induced Activities

mild-agonist

agonist

ER

cMyc

ER

cMyc

MCF7

EPTA-

Gd

TPTA-Gd

T47D cell growth

MCF7 cell growth

MCF7

r1

app

(ER+)=28.5±0.1, n=2

r1

app

(ER-)=19.6

*

Pval

<0.035, paired t-test, n=9

perfused cells

Blood

0.5 cm

DCE-MRI: enhancement profiles

in ER+ and ER- tumors

EPTA-

Gd

TPTA-

Gd

PTA-Gd

ER-

ER+

ER-

ER+

20’ post

ER+

ER-

Principal Component Analysis (PCA)

Eyal

E. et al. JMRI, 2009, 30:989-998

Eigenvalues

1

st

Eigenvector

EPTA-

Gd

TPTA-Gd

PTA-Gd

0.5 cm

0

1

3

2

EPTA-Gd

TPTA-Gd

PTA-

Gd

1

st

eigenvector projection coefficients

N=9

N=4

N=4

*

N=9

N=4

N=4

*

DCE-MRI

Statistics in ER+ and ER- tumors

PCA analysis

p<0.008

Enhancement analysis

20 min post contrast

p<0.05

EPTA

-

Gd

in Solution:

Fast water exchange, efficient paramagnetic r1

relaxivity

and

micromolar

affinity to ER.

in cell cultures (in vitro

)

Binds ER in cells; induces E2-like activity.

E

fficient

ER targeted T1 contrast agent in ER+ vs. ER- cells, 5-fold increased r1

relaxivity in cells upon binding to ER.In orthotopic tumors (in vivo)Efficient ER targeted T1 contrast agent in ER+ tumors.

EPTA-Gd can serve as a targeted probe for molecular imaging of ER in orthotopic breast cancer tumors implanted in miceTPTA-Gd - Binds with high affinity to muscle in vivo and cannot serve as a probe of ER in breast cancers.

Structure

x-ray crystallography of EPTA-

Eu

bound to ER ligand binding domain

Binding site structure

Purple 17

β

- estradiol

Green EPTA

Blue

Gd

ER-LBD dimer bound to EPTA-

Eu

Li MJ, et al Med Chem. 2011, 54:3575-80.

EPTA-Gd

TPTA-Gd

PTA-

Gd

17

β

-estradiol

Tamoxifen

Gunanathan C, et al, Bioconjug Chem. 2007, 18: 1361-5

r1

relaxivity

of EPTA-

Gd